SMEDs Are Working: What the USPTO’s Updated § 101 Patent Eligibility Guidance Means for Innovators

Why It Matters

SMEDs give innovators a clearer path to overcome abstract‑idea rejections, accelerating patent protection for software and other emerging technologies. The practice also reduces examiner workload and improves predictability in the patenting process.

Key Takeaways

• USPTO now encourages separate SMED filings for § 101 rejections
• Early data shows voluntary SMEDs increase allowance rates
• Declarations must focus on “better, cheaper, faster, more efficient” benefits
• Mixing SMEDs with § 103 arguments can dilute their impact

Pulse Analysis

The USPTO’s § 101 eligibility hurdle has long plagued software and biotech innovators, with abstract‑idea rejections stalling commercialization. In response, the agency introduced Rule 132 Subject‑Matter Eligibility Declarations (SMEDs) in late 2025, allowing applicants to present concrete technical benefits alongside their claims. This approach mirrors broader trends in patent law that favor practical application over theoretical concepts, aiming to align the patent system with rapid technological advancement.

The April 30, 2026 memorandum confirms that early adopters of SMEDs are seeing measurable success. Examiners report higher allowance rates when applicants clearly articulate how an invention is "better, cheaper, faster, or more efficient" and provide real‑world evidence of those advantages. Crucially, the guidance reiterates that SMEDs must remain separate from § 103 obviousness arguments, preserving the focus on eligibility and preventing record‑keeping confusion. By mandating that examiners consider all submitted evidence, the USPTO is effectively elevating SMEDs from optional add‑ons to strategic tools in the prosecution toolbox.

Looking ahead, the USPTO hints at further refinements to MPEP § 716.01(c)(III) and promises ongoing data collection to fine‑tune the program. Patent counsel should therefore institutionalize SMED drafting as a standard step in the filing workflow, especially for software, AI, and fintech inventions where abstract‑idea rejections are common. As the practice matures, it is likely to become a benchmark for patent eligibility, shaping both litigation strategy and the broader innovation ecosystem.